A Redox-Active, Compact Molecule for Cross-Linking Amyloidogenic Peptides into Nontoxic, Off-Pathway Aggregates: In Vitro and in Vivo Efficacy and Molecular Mechanisms

Jeffrey S. Derrick, Richard A. Kerr, Younwoo Nam, Shin Bi Oh, Hyuck Jin Lee, Kaylin G. Earnest, Nayoung Suh, Kristy L. Peck, Mehmet Ozbil, Kyle J. Korshavn, Ayyalusamy Ramamoorthy, Rajeev Prabhakar, Edward J. Merino, Jason Shearer, Joo Yong Lee, Brandon T. Ruotolo, Mi Hee Lim

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Chemical reagents targeting and controlling amyloidogenic peptides have received much attention for helping identify their roles in the pathogenesis of protein-misfolding disorders. Herein, we report a novel strategy for redirecting amyloidogenic peptides into nontoxic, off-pathway aggregates, which utilizes redox properties of a small molecule (DMPD, N,N-dimethyl-p-phenylenediamine) to trigger covalent adduct formation with the peptide. In addition, for the first time, biochemical, biophysical, and molecular dynamics simulation studies have been performed to demonstrate a mechanistic understanding for such an interaction between a small molecule (DMPD) and amyloid-β (Aβ) and its subsequent anti-amyloidogenic activity, which, upon its transformation, generates ligand-peptide adducts via primary amine-dependent intramolecular cross-linking correlated with structural compaction. Furthermore, in vivo efficacy of DMPD toward amyloid pathology and cognitive impairment was evaluated employing 5xFAD mice of Alzheimer's disease (AD). Such a small molecule (DMPD) is indicated to noticeably reduce the overall cerebral amyloid load of soluble Aβ forms and amyloid deposits as well as significantly improve cognitive defects in the AD mouse model. Overall, our in vitro and in vivo studies of DMPD toward Aβ with the first molecular-level mechanistic investigations present the feasibility of developing new, innovative approaches that employ redox-active compounds without the structural complexity as next-generation chemical tools for amyloid management.

Original languageEnglish (US)
Pages (from-to)14785-14797
Number of pages13
JournalJournal of the American Chemical Society
Volume137
Issue number46
DOIs
StatePublished - Nov 25 2015

Fingerprint

Amyloid
Peptides
Oxidation-Reduction
Molecules
Alzheimer Disease
Proteostasis Deficiencies
Amyloid Plaques
Pathology
Molecular Dynamics Simulation
Amines
Molecular dynamics
Compaction
Deposits
Ligands
In Vitro Techniques
N,N-dimethyl-p-phenylenediamine
Proteins
Defects
Computer simulation

ASJC Scopus subject areas

  • Chemistry(all)
  • Catalysis
  • Biochemistry
  • Colloid and Surface Chemistry

Cite this

A Redox-Active, Compact Molecule for Cross-Linking Amyloidogenic Peptides into Nontoxic, Off-Pathway Aggregates : In Vitro and in Vivo Efficacy and Molecular Mechanisms. / Derrick, Jeffrey S.; Kerr, Richard A.; Nam, Younwoo; Oh, Shin Bi; Lee, Hyuck Jin; Earnest, Kaylin G.; Suh, Nayoung; Peck, Kristy L.; Ozbil, Mehmet; Korshavn, Kyle J.; Ramamoorthy, Ayyalusamy; Prabhakar, Rajeev; Merino, Edward J.; Shearer, Jason; Lee, Joo Yong; Ruotolo, Brandon T.; Lim, Mi Hee.

In: Journal of the American Chemical Society, Vol. 137, No. 46, 25.11.2015, p. 14785-14797.

Research output: Contribution to journalArticle

Derrick, JS, Kerr, RA, Nam, Y, Oh, SB, Lee, HJ, Earnest, KG, Suh, N, Peck, KL, Ozbil, M, Korshavn, KJ, Ramamoorthy, A, Prabhakar, R, Merino, EJ, Shearer, J, Lee, JY, Ruotolo, BT & Lim, MH 2015, 'A Redox-Active, Compact Molecule for Cross-Linking Amyloidogenic Peptides into Nontoxic, Off-Pathway Aggregates: In Vitro and in Vivo Efficacy and Molecular Mechanisms', Journal of the American Chemical Society, vol. 137, no. 46, pp. 14785-14797. https://doi.org/10.1021/jacs.5b10043
Derrick, Jeffrey S. ; Kerr, Richard A. ; Nam, Younwoo ; Oh, Shin Bi ; Lee, Hyuck Jin ; Earnest, Kaylin G. ; Suh, Nayoung ; Peck, Kristy L. ; Ozbil, Mehmet ; Korshavn, Kyle J. ; Ramamoorthy, Ayyalusamy ; Prabhakar, Rajeev ; Merino, Edward J. ; Shearer, Jason ; Lee, Joo Yong ; Ruotolo, Brandon T. ; Lim, Mi Hee. / A Redox-Active, Compact Molecule for Cross-Linking Amyloidogenic Peptides into Nontoxic, Off-Pathway Aggregates : In Vitro and in Vivo Efficacy and Molecular Mechanisms. In: Journal of the American Chemical Society. 2015 ; Vol. 137, No. 46. pp. 14785-14797.
@article{c6eac08082f34e49a20048d17eebfe8a,
title = "A Redox-Active, Compact Molecule for Cross-Linking Amyloidogenic Peptides into Nontoxic, Off-Pathway Aggregates: In Vitro and in Vivo Efficacy and Molecular Mechanisms",
abstract = "Chemical reagents targeting and controlling amyloidogenic peptides have received much attention for helping identify their roles in the pathogenesis of protein-misfolding disorders. Herein, we report a novel strategy for redirecting amyloidogenic peptides into nontoxic, off-pathway aggregates, which utilizes redox properties of a small molecule (DMPD, N,N-dimethyl-p-phenylenediamine) to trigger covalent adduct formation with the peptide. In addition, for the first time, biochemical, biophysical, and molecular dynamics simulation studies have been performed to demonstrate a mechanistic understanding for such an interaction between a small molecule (DMPD) and amyloid-β (Aβ) and its subsequent anti-amyloidogenic activity, which, upon its transformation, generates ligand-peptide adducts via primary amine-dependent intramolecular cross-linking correlated with structural compaction. Furthermore, in vivo efficacy of DMPD toward amyloid pathology and cognitive impairment was evaluated employing 5xFAD mice of Alzheimer's disease (AD). Such a small molecule (DMPD) is indicated to noticeably reduce the overall cerebral amyloid load of soluble Aβ forms and amyloid deposits as well as significantly improve cognitive defects in the AD mouse model. Overall, our in vitro and in vivo studies of DMPD toward Aβ with the first molecular-level mechanistic investigations present the feasibility of developing new, innovative approaches that employ redox-active compounds without the structural complexity as next-generation chemical tools for amyloid management.",
author = "Derrick, {Jeffrey S.} and Kerr, {Richard A.} and Younwoo Nam and Oh, {Shin Bi} and Lee, {Hyuck Jin} and Earnest, {Kaylin G.} and Nayoung Suh and Peck, {Kristy L.} and Mehmet Ozbil and Korshavn, {Kyle J.} and Ayyalusamy Ramamoorthy and Rajeev Prabhakar and Merino, {Edward J.} and Jason Shearer and Lee, {Joo Yong} and Ruotolo, {Brandon T.} and Lim, {Mi Hee}",
year = "2015",
month = "11",
day = "25",
doi = "10.1021/jacs.5b10043",
language = "English (US)",
volume = "137",
pages = "14785--14797",
journal = "Journal of the American Chemical Society",
issn = "0002-7863",
publisher = "American Chemical Society",
number = "46",

}

TY - JOUR

T1 - A Redox-Active, Compact Molecule for Cross-Linking Amyloidogenic Peptides into Nontoxic, Off-Pathway Aggregates

T2 - In Vitro and in Vivo Efficacy and Molecular Mechanisms

AU - Derrick, Jeffrey S.

AU - Kerr, Richard A.

AU - Nam, Younwoo

AU - Oh, Shin Bi

AU - Lee, Hyuck Jin

AU - Earnest, Kaylin G.

AU - Suh, Nayoung

AU - Peck, Kristy L.

AU - Ozbil, Mehmet

AU - Korshavn, Kyle J.

AU - Ramamoorthy, Ayyalusamy

AU - Prabhakar, Rajeev

AU - Merino, Edward J.

AU - Shearer, Jason

AU - Lee, Joo Yong

AU - Ruotolo, Brandon T.

AU - Lim, Mi Hee

PY - 2015/11/25

Y1 - 2015/11/25

N2 - Chemical reagents targeting and controlling amyloidogenic peptides have received much attention for helping identify their roles in the pathogenesis of protein-misfolding disorders. Herein, we report a novel strategy for redirecting amyloidogenic peptides into nontoxic, off-pathway aggregates, which utilizes redox properties of a small molecule (DMPD, N,N-dimethyl-p-phenylenediamine) to trigger covalent adduct formation with the peptide. In addition, for the first time, biochemical, biophysical, and molecular dynamics simulation studies have been performed to demonstrate a mechanistic understanding for such an interaction between a small molecule (DMPD) and amyloid-β (Aβ) and its subsequent anti-amyloidogenic activity, which, upon its transformation, generates ligand-peptide adducts via primary amine-dependent intramolecular cross-linking correlated with structural compaction. Furthermore, in vivo efficacy of DMPD toward amyloid pathology and cognitive impairment was evaluated employing 5xFAD mice of Alzheimer's disease (AD). Such a small molecule (DMPD) is indicated to noticeably reduce the overall cerebral amyloid load of soluble Aβ forms and amyloid deposits as well as significantly improve cognitive defects in the AD mouse model. Overall, our in vitro and in vivo studies of DMPD toward Aβ with the first molecular-level mechanistic investigations present the feasibility of developing new, innovative approaches that employ redox-active compounds without the structural complexity as next-generation chemical tools for amyloid management.

AB - Chemical reagents targeting and controlling amyloidogenic peptides have received much attention for helping identify their roles in the pathogenesis of protein-misfolding disorders. Herein, we report a novel strategy for redirecting amyloidogenic peptides into nontoxic, off-pathway aggregates, which utilizes redox properties of a small molecule (DMPD, N,N-dimethyl-p-phenylenediamine) to trigger covalent adduct formation with the peptide. In addition, for the first time, biochemical, biophysical, and molecular dynamics simulation studies have been performed to demonstrate a mechanistic understanding for such an interaction between a small molecule (DMPD) and amyloid-β (Aβ) and its subsequent anti-amyloidogenic activity, which, upon its transformation, generates ligand-peptide adducts via primary amine-dependent intramolecular cross-linking correlated with structural compaction. Furthermore, in vivo efficacy of DMPD toward amyloid pathology and cognitive impairment was evaluated employing 5xFAD mice of Alzheimer's disease (AD). Such a small molecule (DMPD) is indicated to noticeably reduce the overall cerebral amyloid load of soluble Aβ forms and amyloid deposits as well as significantly improve cognitive defects in the AD mouse model. Overall, our in vitro and in vivo studies of DMPD toward Aβ with the first molecular-level mechanistic investigations present the feasibility of developing new, innovative approaches that employ redox-active compounds without the structural complexity as next-generation chemical tools for amyloid management.

UR - http://www.scopus.com/inward/record.url?scp=84948664618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948664618&partnerID=8YFLogxK

U2 - 10.1021/jacs.5b10043

DO - 10.1021/jacs.5b10043

M3 - Article

C2 - 26575890

AN - SCOPUS:84948664618

VL - 137

SP - 14785

EP - 14797

JO - Journal of the American Chemical Society

JF - Journal of the American Chemical Society

SN - 0002-7863

IS - 46

ER -